AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by stock analysts at Kepler Capital Markets in a research report issued to clients and investors on Thursday, July 13th. They presently have a GBX 5,500 ($71.62) price objective on the biopharmaceutical company’s stock. Kepler Capital Markets’ price target points to a potential upside of 25.46% from the company’s current price.
AZN has been the topic of several other reports. Liberum Capital reissued a “buy” rating and issued a GBX 5,100 ($66.41) price objective on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a research report on Friday, April 28th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,500 ($71.62) target price on shares of AstraZeneca plc in a research report on Wednesday, March 15th. Societe Generale restated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, March 23rd. Finally, Credit Suisse Group restated an “underperform” rating and issued a GBX 4,000 ($52.09) target price on shares of AstraZeneca plc in a research report on Wednesday, April 19th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 4,932.67 ($64.24).
Shares of AstraZeneca plc (AZN) traded down 0.96% on Thursday, hitting GBX 4384.00. 1,583,746 shares of the stock were exchanged. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The company’s market cap is GBX 55.50 billion. The company has a 50 day moving average of GBX 4,929.68 and a 200 day moving average of GBX 4,860.61.
COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Kepler Capital Markets” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/08/12/astrazeneca-plcs-lonazn-buy-rating-reiterated-at-kepler-capital-markets-updated-updated-updated.html.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.